Literature DB >> 23846935

Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life.

Armin Shahrokni1, Muhammad Wasif Saif.   

Abstract

Due to pancreatic cancer's dismal prognosis, much of management is focused upon palliation and symptom management, and the decision to treat a patient with more aggressive maneuvers must always take into account the impact upon a patient's quality of life. In addition, majority of the patients with advanced pancreatic cancer are elderly. Oncologists are challenged to make tough treatment decisions. Many elderly patients cannot tolerate side effects of chemotherapy, especially the combination regimens. Despite that many patients continue to receive chemotherapy even in the last month of their lives. The effect of referral to palliative care on health-related outcome especially for patients with poor quality of life is still not very clear. The authors will review abstracts that have focused on these fields that were presented at the Annual Meeting of ASCO 2013 (Abstracts #4009, #4053, #6607, #9518, #9538, #9539, #9546, and #9638).

Entities:  

Mesh:

Year:  2013        PMID: 23846935     DOI: 10.6092/1590-8577/1663

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  5 in total

1.  Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature.

Authors:  Yanchu Li; Xianyong Li; Pairotetorsak Tip; Lingyan Zhang
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Reduction of miR-29c enhances pancreatic cancer cell migration and stem cell-like phenotype.

Authors:  Jianxin Jiang; Chao Yu; Meiyuan Chen; Hao Zhang; Se Tian; Chengyi Sun
Journal:  Oncotarget       Date:  2015-02-20

3.  High Rab11-FIP4 expression predicts poor prognosis and exhibits tumor promotion in pancreatic cancer.

Authors:  Yun He; Mengsi Ye; Lingling Zhou; Yunfeng Shan; Guangrong Lu; Yuhui Zhou; Jinwei Zhong; Jihang Zheng; Zhanxiong Xue; Zhenzhai Cai
Journal:  Int J Oncol       Date:  2016-12-30       Impact factor: 5.650

4.  EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer.

Authors:  Qian Wei; Lijuan Wei; Jingya Zhang; Ze Li; Honglei Feng; Li Ren
Journal:  Mol Med Rep       Date:  2020-07-28       Impact factor: 2.952

5.  Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness.

Authors:  Tao Peng; Wei Zhou; Feng Guo; He-Shui Wu; Chun-You Wang; Li Wang; Zhi-Yong Yang
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.